A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
The covid-19 vaccine developed by the Gamaleya Research Institute, part of the Russian Ministry of Health, has an efficacy of 91.6%, according to interim results from a phase III trial. 1 The findings, published in the Lancet, showed that the two dose regime of the viral vector vaccine was generally well tolerated with no associated serious adverse events and similar efficacy in those aged over and under 60. NEWS The BMJ Cite this as: BMJ 2021;372:n309 http://dx.doi:10.1136/bmj.n309 pmid:33531342 fatcat:a2greh465je7raykh6psnj2pc4